Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04722068 · ClinicalTrials.gov registry record · NA
Regeneron 1331 Kinetics Sub-Study HoFH
A NA study, sponsored by University of Pennsylvania.
- Completed
- Registry status
- NA
- Development phase
- 4
- Enrollment target
NCT04722068: Completed NA study, sponsored by University of Pennsylvania.
NCT04722068 is a NA study that has completed, run by University of Pennsylvania. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04722068, a NA study, has completed, sponsored by University of Pennsylvania.
- COMPLETED
- Registry status
- NA
- Development phase
- 4 participants
- Enrollment target
Study Summary
To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH subjects.
Interventions
- OTHER Kinetics test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2016-10-07 |
| Est. Completion | 2021-01-01 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04722068
The ClinicalTrials.gov registry entry for NCT04722068 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 4 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Kinetics test is the first listed.
NCT04722068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04722068 about?
NCT04722068 is a clinical study titled "Regeneron 1331 Kinetics Sub-Study HoFH". To evaluate the lipoprotein kinetics of subjects enrolled in the R1500-CL-1331 clinical trial (NCT02265952) to assess the mechanism by which the evinacumab may affect lipid levels in HoFH subjects.
What is the current status of trial NCT04722068?
This trial is currently completed. It is a NA study. The enrollment target is 4 participants. The study started on 2016-10-07. Estimated completion is 2021-01-01.
What interventions are being tested in trial NCT04722068?
The interventions under investigation include: Kinetics test (OTHER).
Who is sponsoring clinical trial NCT04722068?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.